Waters[™]

Automated Solid-Phase Extraction for the Analysis of Metanephrine and Normetanephrine from Plasma using ACQUITY UPLC-MS/MS for Clinical Research

Heather A. Brown, Lisa J. Calton

Waters Corporation



For research use only. Not for use in diagnostic procedures.

Abstract

This application note demonstrates the use of LC-MS/MS for analysis of metanephrines in clinical research to addresses the shortcomings of traditional methods such as immunoassay and HPLC with electrochemical detection.

Benefits

- · Reduced operator involvement through automation of SPE
- · Facilitate high sample throughput using the multiwell plate format
- · Reduce turnaround time and increase batch size via shortened chromatography

Introduction

Analysis of plasma metanephrines is typically performed by HPLC with electrochemical detection¹ (ECD) methods which are usually labor intensive and can result in relatively low analytical specificity. Extended chromatography and time consuming sample preparation are usually needed to resolve interferences, impacting turnaround times. Relatively few automated immunoassay methods are available for plasma metanephrines, and many of the commercial methods also suffer from interference and poor analytical specificity.

The polar nature and low concentration of metanephrines in plasma pose both extraction and chromatographic separation challenges. A recent publication describes an online automated weak cationic exchanger (WCX) solid phase extraction (SPE) with hydrophilic interaction (HILIC) HPLC and analytically selective and sensitive MS detection.²

Here we present the further development of this method to allow automated offline SPE using Oasis WCX µElution plates utilising a Tecan liquid handling system (LHS). The extracted plate is placed onto the ACQUITY Sample Manager and is ready for analysis using ACQUITY UPLC BEH Amide Column chemistry coupled to a Xevo TQ MS Detector. Measurement of plasma metanephrine (M) and normetanephrine (NM) provides the opportunity to perform clinical research into the pathogenesis of disease states associated with catecholamine excess.



Figure 1. Tecan Freedom EVO 100 and the Waters ACQUITY UPLC Xevo TQ MS Detector

Experimental

UPLC conditions

Column:	ACQUITY UPLC BEH Amide 1.7 μm , 2.1 x 50 mm (p/n 186004800)
Column temp.:	35 °C
Sample temp.:	4 °C
Injection volume:	20 µL (PLNO)
Weak needle wash:	Acetonitrile
Strong needle wash:	Water

Flow rate:	200 µL/min	
Mobile phase A:	100 mM ammonium formate, pH 3.0 with formic acid (aq)	
Mobile phase B:	Acetonitrile	
Gradient:	2 to 35% linear gradient of Mobile Phase A over 3 minutes; 1 minute hold then step gradient to initial conditions with 1 minute re-equilibration	
Run time:	5 min	
MS conditions		
Instrument tuned to unit resolution on MS1 and MS2 (0.7 FWHM)		
System:	Xevo TQ MS Detector	
System: Acquisition mode:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions	
System: Acquisition mode: Ionization mode:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions ESI positive	
System: Acquisition mode: Ionization mode: Capillary voltage:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions ESI positive 0.6 kV	
System: Acquisition mode: Ionization mode: Capillary voltage: Dwell time:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions ESI positive 0.6 kV 0.04 sec	
System: Acquisition mode: Ionization mode: Capillary voltage: Dwell time: Interscan and inter channel delay 0.01 sec Source temp.:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions ESI positive 0.6 kV 0.04 sec 150 °C	
System: Acquisition mode: Ionization mode: Capillary voltage: Dwell time: Interscan and inter channel delay 0.01 sec Source temp.: Desolvation temp.:	Xevo TQ MS Detector Multiple Reaction Monitoring (MRM) – see Table 2 for ion transitions ESI positive 0.6 kV 0.04 sec 150 °C	

application manager.

Analyte	Precursor ion (<i>m/z</i>)	Product ion (<i>m/z</i>)	Cone voltage	Collision energy
Metanephrine	180.0	148.0	30	16
Normetanephrine	166.0	134.0	32	18
² H ₃ Metanephrine	183.0	151.0	30	16
$^{2}H_{3}$ Normetanephrine	169.0	137.0	32	18

Table 2. Guideline MRM parameters: Conditions optimized to facilitate in-source loss of water. Precursor ions represent the $[M+H-H_2O]^+$ species.

Sample preparation

Calibrators were prepared fresh for each analysis using stripped serum spiked with solvent stocks from independently weighed solid HCl salts of metanephrine (M) and normetanephrine (NM) (Sigma-Aldrich, Dorset, UK). Quantification followed blank-correction for endogenous metanephrines.

A working solution of ${}^{2}H_{3}$ M, and ${}^{2}H_{3}$ NM internal standard (IsoSciences, King of Prussia, PA, USA) was prepared daily by 500-fold dilution of an acidified stock into LC-MS grade water.

Sample extraction

Samples, calibrators, and quality control materials were centrifuged at a minimum of 10,000 *g* to remove clots and debris. Minimum of 250 µL was transferred to barcode-labelled tubes and placed on the Tecan Freedom EVO 100 liquid handling system (LHS). All SPE solvents, calibrators and working internal standards, Oasis WCX µElution (p/n 186002499), mixing and collection plates (p/n 186002482 and 186002481) were positioned onto the LHS.

LHS-automated steps:

- \cdot Mixing of 200 μL sample with 200 μL internal standard
- $\cdot\,$ Transfer of 200 μL internal standard + sample mixture to the methanol-conditioned and water-equilibrated Oasis WCX $\mu Elution$ plate
- \cdot Sequential washing with 200 μL each of water, methanol, and 0.2 % (v/v) formic acid in acetonitrile
- $\cdot\,$ Elution with 2 x 50 μL passes of 2% (v/v) formic acid in acetonitrile into the collection plate.

Utilizing the load-ahead feature, an injection-to-injection time of approximately 5.5 min was achieved.

Prepare samples, reagents and mobile phases	t = 0 mins
Tecan LHS mixes samples and internal standards	t = 20 mins
µElution plate conditioned and equilibrated	t = 28 mins
Samples loaded and washed on µElution plate	t = 78 mins
Samples eluted from µElution plate	t = 90 mins
Samples analysed by LC-MS/MS	t = 340 mins

Table 1. Typical workflow for the analysis of 45 samples.

Method conditions

Two blank injections were performed to allow thorough column equilibration before running sample lists. Careful attention was paid to positioning and priming of ACQUITY UPLC lines to maintain HILIC chromatography conditions.

Results and Discussion

The limit of detection (LOD) and LLOQ were interpolated from mean peak to peak signal to noise ratios (S:N) from extracted ion chromatograms of 10 samples with the lowest signal to noise ratio analysed for method comparison. The calculated LLOQ S:N >10 were 45 and 127 pmol/L for M and NM, respectively. The LOD was calculated at S:N > 5, therefore, these values were half the LLOQ. Example extracted ion chromatograms in low concentration extracted plasma samples are shown in Figure 2.



Figure 2. Normetanephrine (287 pmol/L) and metanephrine (137 pmol/L) in extracted plasma; peak to peak signal to noise ratios of 23 for both.

Within- and between-batch imprecision determined by replicate extraction and analysis over 5 days of a human plasma base pool spiked to 3 concentrations revealed mean within batch imprecision of <7.6 and <5.6 % coefficient of variation (CV) for M and NM, respectively. The same data reveals the mean between batch CV as <7.5 and <12.8 % for M and NM, respectively.

Linearity of detector response up to 24.55 nmol/L was demonstrated with the 8-point calibration curve showing a coefficient of determination >0.995 and <15 % deviation from nominal concentrations. Additionally, linearity of detector response upon extraction of an 8 nmol/L spiked sample, sequentially diluted with stripped serum, was shown.

Mean Oasis WCX µElution plate SPE efficiency was calculated as the peak area ratio of pre- to postextraction spiked plasma (n=3) was 97 and 95 % for M and NM, respectively. Matrix effects were evaluated from the peak area of the post-extraction spiked samples (n=6) taken as a percentage of extraction solvent spiked to equivalent concentrations. Mean (range) matrix effects were 16.4 (1.8 % to 35.0) % ion enhancement for M and 8.7 (3.6 % suppression to 19.4) % enhancement for NM. Calculations using analyte: internal standard peak area response indicated matrix effect compensation by the internal standard with a mean net matrix effect (range) of 4.0 (0.5 to 6.0) % enhancement for M and 0.3 (3.3 % suppression to 7.5) % enhancement for NM.

Comparison was made using 50 plasma reference samples analysed by an online SPE LC-MS/MS method.²

Deming regression conducted with Analyse-it for Microsoft Excel for Windows 2003 showed neither significant proportional nor constant bias across the measured range of 87–4455 pmol/L for M (p>0.05). Proportional bias of 15 % was found across the measured range of NM 300–14459 pmol/L (p<0.02), however, this became insignificant when limiting the comparison to below the upper limit of the reference sample interval (<1070 pmol/L; p=0.48).



Figure 3. Deming regression comparing online SPE HPLC-MS/MS with the developed offline UPLC-MS/MS method.

Solvent standards of potential endogeneous and exogeneous isobaric interferents were injected and chromatograms were interrogated for peak and baseline interferences. Epinephrine, norepinephrine and dopamine contributed to a high baseline signal in the NM MRM. MS1 scans showed abundant NM precursor m/z 166 in the source. MS2 scans of potentially interfering substances under M and NM-optimised conditions indicated low levels of product ions which may pose isobaric interference with the NM 166>134 MRM transition when operating at very low resolution. For this reason, operation of MS2 at unit resolution or higher (FWHM \leq 0.7) is recommended.

Conclusion

The use of LC-MS/MS for analysis of metanephrines in clinical research addresses the shortcomings of traditional methods such as immunoassay and HPLC with electrochemical detection. Analytically sensitive

and selective quantification of low concentrations of metanephrines in plasma is possible by coupling automated SPE and ACQUITY UPLC separation with MRM analysis using the Xevo TQ MS Detector. Eluates from the Oasis WCX µElution Plate are directly compatible with the LC-MS/MS system, negating sample evaporation and reconstitution required with strong cationic exchangers.³ Simplified processing of large numbers of samples is possible with reduced risk of preparative errors by taking advantage of the Tecan LHS.

References

- 1. Lenders JW *et al*. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. *Clin Chem* 1993;39(1):97-103.
- 2. De Jong WHA *et al.* Plasma free metanephrine measurement using automated online solid-phase extraction HPLC-tandem mass spectrometry. *Clin Chem* 2007;53(9):1684-1693.
- 3. Clarke MW *et al.* Improved plasma free metadrenaline analysis requires mixed mode cation exchange solid-phase extraction prior to liquid chromatography tandem mass spectrometry. *Ann Clin Biochem* 2011;48:352-357.

Acknowledgement

Bob Peaston, Erin Chambers and Kendon Graham are thanked for helpful discussions regarding the development of the SPE extraction and LC method.

Featured Products

MassLynx MS Software <https://www.waters.com/513662> TargetLynx <https://www.waters.com/513791> ACQUITY UPLC System <https://www.waters.com/514207>

720004822, February 2014

©2019 Waters Corporation. All Rights Reserved.